Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 2
Semaglutide review: weight loss and CRP
A pooled review of nine trials found subcutaneous semaglutide cut body weight and C-reactive protein versus placebo in adults with overweight or obesity.
Semaglutide and CRP in obesity: 2026 data
A 2026 meta-analysis of nine trials found semaglutide cut body weight 12% and C-reactive protein 41% versus placebo in non-diabetic adults with obesity.
Semax for ADHD: evidence in young adults
Semax modulates BDNF and dopamine signalling in animal studies. It has no approved use for ADHD and no published safety data in adolescents or young adults.
Hair shedding after tirzepatide
Hair shedding after tirzepatide needs assessment, not an untested swap from minoxidil to GHK-Cu or KPV.
Needle reuse and vial contamination
A used needle can carry material into another vial. CDC injection-safety guidance explains why each vial entry needs new sterile equipment.
Weight loss as disease modification
A new review asks when reducing excess adiposity changes disease outcomes, and where evidence for semaglutide and tirzepatide remains limited.
GLP-1 drugs in lipedema: survey evidence
A 2026 Obesity Pillars survey collected self-reported outcomes from people with lipedema on GLP-1 or GLP-1/GIP drugs. Patient data, but no controlled trial.
Semaglutide and NAION: reading the reply
Heberer, Bress, and Lee reply in JAMA Ophthalmology to a critique of their semaglutide-NAION research, defending active comparator design.
Semaglutide and NAION: the data debate
A 2026 JAMA Ophthalmology letter questions the evidence linking semaglutide to NAION, after the EMA listed the condition as a very rare side effect in 2025.
Semax and Selank: reports vs research
First-day users describe mild stimulation, appetite suppression, and reduced anxiety. Here is what the published research covers and where it stops.
SURMOUNT-1: glycemia markers and T2D risk
A 2026 post hoc SURMOUNT-1 analysis tested three glycemia markers in prediabetes. OGTT one-hour glucose caught 83% of T2D progressors. HbA1c alone missed 53%.
Tirzepatide and bullous pemphigoid
A case report links tirzepatide to bullous pemphigoid, an autoimmune blistering skin condition. Here is what the evidence shows and what stays unknown.